Navigation Links
Ontario minister seconds patient-pay plan for expensive cancer drugs

The idea of permitting hospitals to effect a charge on cancer patients for powerful, intravenous medications, not sponsored by the public health-care //system, is being seriously considered by Ontario's Health Minister.

George Smitherman said "There's no final decision yet. We've done some due diligence and obviously we're closer to having a policy. And in my heart, I believe it's the right thing said in a telephone interview yesterday. I have a responsibility to consider this once I have seen the final advice and to make sure that it's the right thing at the right time for Ontario."

The patients would be allowed to pay for those cancer drugs that have the approval of Health Canada but are frightfully expensive, which may be needed to extend the life of patients suffering from incurable cancers. The proposal will permit thousands of Ontario patients to buy the IV drugs at half the price in comparison to the United States Market.

According to Carolyn Henry, group leader of the London and District Myeloma Support Group, said "Imagine delaying treatment for lack of money, having to fundraise for treatment, putting your kids' postsecondary education at risk, potentially having to sell your house because you can't keep up the mortgage payments, which you incurred to pay for treatment, because you can't work.”

Bill Evans, an oncologist and president of the Juravinski Cancer Centre in Hamilton, stating that many new cancer drugs are awfully expensive said "People are going to seek these things out and they are willing to pay for them. What are you going to do -- say no, and inconvenience people? Or try to help with the safety and continuity of their care by making them available?"


'"/>




Page: 1

Related medicine news :

1. Nurses In Ontario demands Safe Disposable Needles
2. Ontario Institute for Cancer Research is funded $142 million
3. Students wants to extent Tution waiver in Ontario
4. Patients In Ontario Wait Longer For Treatment
5. Ontario Unprepared To Deal With Flu Pandemic
6. Ontario’s Entire Drug System Undergoes a Revam
7. Chemotherapy Queues in Ontario Stay Steady
8. Ontario Ranks Highest in Free Bird Flu Vaccination Rates
9. Ontario Medical Association Planning To Lure Back Expat Doctors
10. Ontario Addresses Shortage of Transplant Organs
11. Ontario Continues Support for Autistic Children
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger Pigott ... LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach ... from the firm’s global Life Sciences & Medical Technology Group have been featured speakers ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
Breaking Medicine Technology: